Constipation: When to See a Doctor, Causes, and Treatments

Constipation is a common symptom, not a diagnosis by itself, and it is defined clinically as fewer than three spontaneous bowel movements per week, straining on more than a quarter of attempts, or a persistent sense of incomplete evacuation. Most constipation is functional and resolves with fiber, fluids, and an osmotic laxative such as polyethylene glycol (PEG, sold as MiraLAX). The clinically important question is not "is my constipation bad" but "does it have a feature that changes what I should do next," because a handful of specific signs (rectal bleeding, unintended weight loss, new onset after age 50, or no bowel movement for more than a week) shift the right response from home management to a same-day medical evaluation. This article separates what is well established (fiber and osmotic laxatives work; certain symptoms warrant urgent workup) from what is plausible but not rigorously quantified on this page (exact trial response rates for individual prescription drugs, which vary by study and should be confirmed against the current FDA label before being treated as fixed numbers).

When should you worry about constipation?

Most constipation is self-limited. Gastroenterology guidance generally treats a specific set of "alarm features" as the trigger for further workup rather than watchful waiting: rectal bleeding, unintentional weight loss, iron-deficiency anemia, a palpable abdominal or rectal mass, and new-onset constipation in adults over age 50. These features raise concern for colorectal cancer, inflammatory disease, or a structural obstruction and are the standard reason clinicians order colonoscopy rather than starting empiric laxative therapy.

The red-flag checklist

Contact your doctor the same day, or go to an emergency department, if constipation occurs alongside any of the following:

• Bright red blood or dark, tarry stool. This can indicate an anal fissure, a colorectal lesion, or ischemic colitis, and the distinction matters for how urgently it is evaluated.
• Unintentional weight loss. Losing a meaningful amount of body weight without trying, over a period of months, is a standard alarm feature in gastroenterology.
• Fever with abdominal distension. This combination raises concern for infectious colitis or bowel obstruction and generally needs same-day evaluation.
• Severe, worsening abdominal pain that does not improve after passing gas or stool.
• No bowel movement for more than seven days despite consistent use of an over-the-counter laxative.
• New saddle-area numbness, leg weakness, or urinary retention. These can signal cauda equina syndrome, a surgical emergency, and constipation is sometimes an incidental accompanying complaint rather than the cause.

Why age 50 matters

New-onset constipation after age 50 carries a higher pretest probability of a significant colorectal finding than the same symptom in a younger person, which is one reason average-risk colorectal cancer screening is now generally recommended starting at age 45 in U.S. guidance, with any alarm symptom accelerating that timeline regardless of age. Specific incidence figures for "percentage of new-onset constipation patients over 50 found to have a lesion" vary across studies and should be confirmed against a current, verifiable source before being quoted as a precise statistic; we are not repeating a specific percentage here because the original source citation for it could not be verified.

When waiting is reasonable

If none of the alarm features above are present, the constipation has lasted under two to three weeks, and there is an obvious precipitating cause (recent travel, new opioid prescription, a low-fiber stretch of eating), a trial of lifestyle changes for two to four weeks before escalating care is a reasonable approach used in general practice. This is judgment guidance, not a guideline citation, and it does not apply once any red flag appears.

What causes constipation?

Constipation results from slowed colonic transit, impaired defecatory mechanics (the coordination needed to actually pass stool), or both. Clinicians commonly separate it into normal-transit constipation, slow-transit constipation, defecatory disorders, and mixed presentations, per the Rome IV functional gastrointestinal disorder framework. Secondary causes, meaning constipation driven by another condition or a medication, are common and are often overlooked in favor of assuming a purely dietary cause.

Diet, fluid, and activity

Low fiber intake is the most modifiable dietary risk factor. Most adults in the United States eat well below commonly cited fiber targets (the Dietary Guidelines for Americans set adult targets in the range of roughly 25 to 38 grams per day). Dehydration compounds the problem because the colon reabsorbs water from stool, and inadequate fluid intake hardens stool further. Physical inactivity independently slows colonic motility, which is part of why postoperative patients and nursing-home residents have disproportionately high constipation rates.

Medications as a cause

Medications are a frequently cited driver of secondary constipation. Commonly implicated classes include:

• Opioids. These act on mu-receptors in the gut wall and reduce peristaltic contractions. Opioid-induced constipation is common enough among people on regular opioid therapy that it is treated as an expected side effect requiring proactive management rather than an occasional complication.
• Calcium channel blockers, particularly verapamil.
• Tricyclic antidepressants, through anticholinergic effects that slow gut motility.
• Iron supplements, which can irritate the colonic lining and alter stool consistency.
• Anticholinergic antihistamines such as diphenhydramine (Benadryl).
• GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which slow gastric emptying and gut transit. These drugs are still relatively new to widespread use (current as of 2025), and readers should check the current FDA label or a verified trial publication for exact incidence figures rather than relying on a single quoted percentage, since numbers differ across trials, doses, and populations.

Metabolic, structural, and neurological causes

Hypothyroidism, diabetes, hypercalcemia, and hypokalemia can all impair intestinal motility, which is why basic labs (thyroid-stimulating hormone, calcium, a metabolic panel) are a standard part of the workup for unexplained chronic constipation before more invasive testing.

Pelvic floor dyssynergia, in which the muscles that should relax during a bowel movement instead contract, is a recognized and common finding among patients referred to specialized motility clinics for constipation that has not responded to standard treatment. Spinal cord injury above roughly the mid-thoracic level can cause neurogenic bowel with markedly slowed transit. Hirschsprung disease is usually diagnosed in infancy but occasionally presents in adulthood as refractory constipation.

How is constipation diagnosed?

Diagnosis starts with history and the Rome IV symptom criteria, then moves to targeted testing only if alarm features are present or first-line treatment fails.

Rome IV criteria (used by clinicians, not a self-diagnosis tool)

Functional constipation is generally defined as having at least two of the following for three or more months, with onset at least six months before diagnosis:

1. Straining on more than a quarter of bowel movements
2. Lumpy or hard stool on more than a quarter of bowel movements
3. Sensation of incomplete evacuation on more than a quarter of bowel movements
4. Sensation of anorectal blockage on more than a quarter of bowel movements
5. Needing manual maneuvers to have a bowel movement on more than a quarter of attempts
6. Fewer than three spontaneous bowel movements per week

Loose stools should not be the dominant symptom, and irritable bowel syndrome with constipation needs to be considered as an alternative diagnosis.

Exam and baseline labs

A physical exam checks for abdominal distension or a mass, and a digital rectal exam evaluates sphincter tone, stool in the rectum, and signs of prolapse or rectocele. Baseline labs commonly include a complete blood count, thyroid-stimulating hormone, and a metabolic panel.

When testing goes further

If empiric treatment does not work after several weeks, motility testing becomes reasonable:

• Wireless motility capsule measures whole-gut and segmental transit time without invasive testing.
• Anorectal manometry measures sphincter pressures, rectal sensation, and reflex function.
• Defecography (conventional or MRI) visualizes structural problems like rectocele or intussusception during a simulated bowel movement.
• Colonoscopy is reserved for alarm features, incomplete colorectal cancer screening, or suspicion of a structural cause, not for routine constipation without red flags.

Treatment: a step-by-step approach

Treatment generally follows a ladder: lifestyle change, then over-the-counter laxatives, then prescription agents, then procedural options for cases that do not respond to anything else.

Step 1: fiber and fluid

Soluble fiber, particularly psyllium, has the strongest and most consistent evidence among dietary fiber types for improving stool frequency and consistency. Insoluble fiber (wheat bran) increases stool bulk but tends to cause more bloating and is generally considered less effective at softening stool. Adequate fluid intake supports fiber's effect; fiber without enough fluid can worsen constipation rather than help it.

Step 2: over-the-counter laxatives

Polyethylene glycol is generally regarded, across the published trial literature, as more effective and better tolerated than lactulose for chronic constipation, though exact head-to-head numbers vary by study and should be checked against a specific trial before being cited precisely. Docusate sodium is widely prescribed despite comparatively weak trial support; more than one controlled study has found it performs no better than placebo for constipation in specific populations such as patients on opioids for cancer pain.

Step 3: prescription secretagogues

If laxatives fail after several weeks of consistent use, FDA-approved secretagogues become a reasonable next step for chronic idiopathic constipation:

• Linaclotide (Linzess), a guanylate cyclase-C agonist that increases intestinal fluid secretion.
• Plecanatide (Trulance), a related mechanism with a somewhat lower reported rate of diarrhea in trials than linaclotide.
• Lubiprostone (Amitiza), a chloride channel activator approved for chronic idiopathic constipation and for opioid-induced constipation.
• Prucalopride (Motegrity), a selective 5-HT4 receptor agonist that accelerates whole-gut transit.

These are prescription, FDA-approved drugs for chronic idiopathic constipation (not off-label uses), but exact response rates from their pivotal trials differ by study design and should be verified against the current FDA label or the original trial publication rather than quoted from memory. This article intentionally avoids restating specific trial percentages that could not be verified against the primary literature for this draft.

Step 4: biofeedback for pelvic floor dysfunction

Biofeedback therapy is considered first-line treatment for defecatory disorders caused by pelvic floor dyssynergia, and multiple controlled comparisons have found it more effective than laxatives or muscle relaxants specifically for this subtype. This is a mechanism-matched treatment: it works because dyssynergia is a coordination problem, not a transit problem, so a chemical laxative does not fix the underlying issue.

Step 5: surgical and procedural options

Subtotal colectomy is reserved for severe, refractory slow-transit constipation that has failed all pharmacologic options, and only after motility testing confirms slow transit and excludes a defecatory disorder (since colectomy does not fix dyssynergia). Reported satisfaction rates vary widely across case series, reflecting how much outcomes depend on careful patient selection. Sacral nerve stimulation, developed originally for fecal incontinence, has shown early signal for slow-transit constipation in small trials but is not an FDA-approved indication for constipation.

Constipation during pregnancy

Constipation is common in pregnancy, driven mainly by progesterone-related smooth muscle relaxation and mechanical compression of the colon by the growing uterus. Fiber and fluid are first-line management. Stimulant laxatives are generally avoided, particularly early in pregnancy, and osmotic agents such as PEG and lactulose are generally considered to have acceptable safety profiles throughout pregnancy, though large controlled trial data specifically in pregnant populations are limited. Anyone pregnant should confirm any laxative choice with their obstetric provider rather than relying on general guidance.

Opioid-induced constipation

Opioid-induced constipation deserves separate attention because standard laxatives are often insufficient on their own. Mu-opioid receptors in the gut wall directly slow motility, which is why peripherally acting mu-opioid receptor antagonists (PAMORAs) were developed to target the mechanism rather than just add more general laxative effect. A recent qualitative study of patients with cancer and their healthcare professionals found that opioid-induced constipation is frequently under-discussed and under-treated in clinical encounters, with patients often not raising it and clinicians not systematically screening for it (Pain et al., 2026). That finding supports proactively asking about bowel function whenever opioids are prescribed, rather than waiting for a patient to volunteer it.

PAMORA options

• Methylnaltrexone (Relistor), given subcutaneously.
• Naloxegol (Movantik), an oral once-daily option.
• Naldemedine (Symproic), an oral once-daily option.

Specific response rates from each drug's pivotal trial vary by study and should be confirmed against the current FDA label before being cited as a fixed number.

Constipation and GLP-1 / GIP-GLP-1 receptor agonists

GLP-1 receptor agonists are now among the most widely prescribed drug classes in the United States (as of 2025), and constipation is a recognized, dose-dependent side effect tied to their effect of slowing gastric and intestinal transit. Trials of semaglutide and tirzepatide have both reported meaningfully higher constipation rates than placebo, but the exact percentages differ across trials, doses, and formulations, and this page does not restate a specific figure without a verified source. Management follows the same laxative ladder described above. Starting an osmotic laxative such as PEG proactively at the time of dose escalation is a reasonable clinical strategy, though it has not been specifically tested in a dedicated randomized trial in GLP-1 users to our knowledge. Slower dose titration is a generally accepted way to reduce gastrointestinal side effects across this drug class.

Constipation in older adults

Constipation is substantially more common in adults over 65 than in younger adults, and rates are reported to be especially high in nursing-home populations. Contributing factors include polypharmacy, reduced mobility, inadequate fluid intake, and age-related changes in bowel reflexes.

Stimulant laxatives such as senna and bisacodyl are generally considered safe for long-term use in older adults, and the older concern that they cause permanent "lazy bowel" or nerve damage is not well supported by current evidence. Melanosis coli, a benign pigment change in the colon lining sometimes seen with long-term stimulant laxative use, has no confirmed link to cancer risk. Osmotic agents including PEG are generally preferred and considered safe in this population.

Mineral oil should generally be avoided in older adults with swallowing difficulty (dysphagia), because aspiration can cause lipoid pneumonia, a serious complication that is often missed initially.

What is established, what is plausible, and what is not established

Established: fiber, fluid, and osmotic laxatives (especially PEG) improve stool frequency and consistency for most people with functional constipation. Specific alarm features (rectal bleeding, unintended weight loss, new onset after 50, fever with distension, neurological symptoms) warrant prompt medical evaluation rather than home management. Biofeedback is the appropriate first-line treatment specifically for pelvic floor dyssynergia, not for slow-transit constipation.

Plausible but not rigorously quantified here: exact response rates and adverse-event rates for individual prescription secretagogues and PAMORAs, since these numbers come from specific trials that vary by dose, population, and endpoint definition and were not independently re-verified for this draft. The idea that starting a laxative proactively at GLP-1 dose escalation reduces constipation severity is clinically reasonable but has not been confirmed in a dedicated trial to our knowledge.

Not established on the evidence available here: a single precise percentage for how often new-onset constipation after age 50 reflects a significant colorectal lesion. The original source for that figure could not be verified, so it has been removed rather than repeated.

A decision framework: what changes what you should do

This is not a diagnostic tool and does not replace a clinical evaluation. It is meant to help a reader sort a symptom into the right lane.

Lane 1: Same-day medical evaluation. Any of: rectal bleeding or black stool, unintentional weight loss, fever with abdominal distension, severe pain unrelieved by passing gas or stool, no bowel movement for more than seven days despite laxative use, or new saddle-area numbness, leg weakness, or urinary retention. Do not wait for a fiber trial to work before seeking care in this lane.

Lane 2: Routine medical evaluation within days to a couple of weeks. New-onset constipation after age 50 with no other alarm feature, constipation that has lasted more than three months (meeting the Rome IV chronic threshold), or constipation that has not responded to four weeks of consistent fiber plus an osmotic laxative.

Lane 3: Reasonable to self-manage for two to four weeks first. No alarm features, duration under two to three weeks, and an identifiable precipitating cause such as recent travel, a new opioid prescription, or a low-fiber stretch. First move: increase fiber and fluid, add PEG if no improvement in a few days.

Special case, on opioids: do not wait for constipation to become severe before starting prevention. If a scheduled opioid is started, ask the prescriber about a bowel regimen at the same visit rather than after constipation develops. If two laxative classes fail, ask specifically about a PAMORA (naloxegol, methylnaltrexone, or naldemedine) rather than escalating stimulant laxative doses indefinitely.

Special case, on a GLP-1 receptor agonist: constipation that starts or worsens after a dose increase is a recognized, expected side effect for many patients, not necessarily a sign of anything else, but it should still be mentioned to the prescriber, especially if it is severe or accompanied by significant abdominal pain, since severe GI symptoms on these drugs occasionally warrant dose adjustment.

Special case, pregnancy: treat as Lane 3 by default (fiber, fluid, PEG or lactulose) but confirm any laxative choice with your obstetric provider, and avoid stimulant laxatives without their guidance.